60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

August 12, 2024

https://www.globenewswire.com/news-release/2024/08/12/2928485/0/en/60-Degrees-Pharma-Provides-University-of-Kentucky-with-Right-of-Reference-to-ARAKODA-NDA-in-Support-of-SJ733-Phase-IIb-Study.html

WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has granted the University of Kentucky a right of reference to the Company’s new drug application (“NDA”) for ARAKODA® (tafenoquine).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.